Ahmed Abdelhak, MD

Title(s)Postdoctoral Scholar, Neurology
SchoolSchool of Medicine
Address675 Nelson Rising Lane
San Francisco CA 94158
Phone--
ORCID ORCID Icon0000-0001-9731-4169 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Ain Shams University , Cairo, EgyptMD2010Human Medicine
    University of Ulm, Ulm, GermanyDoctor of Medicine (PhD equivalent)2017Clinical Neurology
    University of Bordeaux, Bordeaux, France MS.c2019Neuroscience
    German Medical Board, Stuttgart, Germany German Neurology Board Certification2022Clinical Neurology
    Collapse Awards and Honors
    Weill Institute for Neurosciences2021  - 2022Junior Investigator Award - Establishing novel blood-based biomarkers to track MS activity
    ECTRIMS - DGN2016  - 2020Travel Grants

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS) - Phase 2
    German Multiple Sclerosis Society, German Multiple Sclerosis Trust Jan 1, 2021 - Dec 31, 2023
    Role: Principle Investigator
    Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS):
    German Multiple Sclerosis Society Apr 1, 2018 - Apr 30, 2022
    Role: Principle Investigator

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain. 2022 Sep 09. Abu-Rumeileh S, Abdelhak A, Foschi M, D'Anna L, Russo M, Steinacker P, Kuhle J, Tumani H, Blennow K, Otto M. PMID: 36083979.
      View in: PubMed   Mentions:
    2. Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis. Neurology. 2022 Aug 29. Cordano C, Nourbakhsh B, Yiu HH, Papinutto N, Caverzasi E, Abdelhak AC, Cosima C Oertel F, Beaudry-Richard A, Santaniello A, Sacco S, Bennett DJ, Gomez A, Sigurdson CJ, Hauser SL, Magliozzi R, Campbell Cree BA, Henry RG, Green AJ. PMID: 36038272.
      View in: PubMed   Mentions:
    3. Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease. Biomedicines. 2022 Aug 02; 10(8). Huss A, Abdelhak A, Mayer B, Tumani H, Müller HP, Althaus K, Kassubek J, Otto M, Ludolph AC, Yilmazer-Hanke D, Neugebauer H. PMID: 36009416; PMCID: PMC9405121.
      View in: PubMed   Mentions:
    4. Retinal arteriolar parameters as a surrogate marker of intracranial vascular pathology. Alzheimers Dement (Amst). 2022; 14(1):e12338. Abdelhak A, Solomon I, Montes SC, Saias A, Cordano C, Asken B, Fonseca C, Oertel FC, Arfanakis K, Staffaroni AM, Kramer JH, Geschwind M, Miller BL, Elahi FM, Green AJ. PMID: 35814617; PMCID: PMC9257197.
      View in: PubMed   Mentions:
    5. Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022 Jun 16. Abdelhak A, Cordano C, Boscardin WJ, Caverzasi E, Kuhle J, Chan B, Gelfand JM, Yiu HH, Oertel FC, Beaudry-Richard A, Condor Montes S, Oksenberg JR, Lario Lago A, Boxer A, Rojas-Martinez JC, Elahi FM, Chan JR, Green AJ. PMID: 35710320.
      View in: PubMed   Mentions:    Fields:    
    6. Reply to "Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MS". Ann Neurol. 2022 07; 92(1):156. Cordano C, Yiu HH, Abdelhak A, Beaudry-Richard A, Oertel FC, Green AJ. PMID: 35403744.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022 03; 18(3):158-172. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H. PMID: 35115728.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    8. Diagnostic and Prognostic Blood Biomarkers in Transient Ischemic Attack and Minor Ischemic Stroke: An Up-To-Date Narrative Review. J Stroke Cerebrovasc Dis. 2022 Mar; 31(3):106292. Foschi M, Padroni M, Abu-Rumeileh S, Abdelhak A, Russo M, D'Anna L, Guarino M. PMID: 35026496.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome. Brain. 2021 06 22; 144(5):e44. Foschi M, D'Anna L, Abdelhak A, Mayer B, Tumani H, Otto M, Abu-Rumeileh S. PMID: 33822000; PMCID: PMC8083498.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    10. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells. 2020 11 25; 9(12). Robinson T, Abdelhak A, Bose T, Meinl E, Otto M, Zettl UK, Dersch R, Tumani H, Rauer S, Huss A. PMID: 33255854; PMCID: PMC7761295.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    11. Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. Biomedicines. 2020 Aug 28; 8(9). Huss A, Senel M, Abdelhak A, Mayer B, Kassubek J, Ludolph AC, Otto M, Tumani H. PMID: 32872144; PMCID: PMC7555392.
      View in: PubMed   Mentions: 6  
    12. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr; 268(4):1133-1170. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. PMID: 32840686; PMCID: PMC7445716.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    13. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. Front Neurol. 2020; 11:608. Huss A, Otto M, Senel M, Ludolph AC, Abdelhak A, Tumani H. PMID: 32765393; PMCID: PMC7378743.
      View in: PubMed   Mentions: 7  
    14. Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study. Contemp Clin Trials Commun. 2020 Jun; 18:100574. Abdelhak A, Huss A, Stahmann A, Senel M, Krumbholz M, Kowarik MC, Havla J, Kümpfel T, Kleiter I, Wüstinger I, Zettl UK, Schwartz M, Roesler R, Friede T, Ludolph AC, Ziemann U, Tumani H. PMID: 32478196; PMCID: PMC7251538.
      View in: PubMed   Mentions:
    15. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? Front Neurol. 2019; 10:280. Abdelhak A, Hottenrott T, Morenas-Rodríguez E, Suárez-Calvet M, Zettl UK, Haass C, Meuth SG, Rauer S, Otto M, Tumani H, Huss A. PMID: 30972011; PMCID: PMC6443875.
      View in: PubMed   Mentions: 24  
    16. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018 10 04; 8(1):14798. Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. PMID: 30287870; PMCID: PMC6172254.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    17. Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients. Ann Neurol. 2018 05; 83(5):1032-1036. Huss A, Abdelhak A, Halbgebauer S, Mayer B, Senel M, Otto M, Tumani H. PMID: 29665046.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation. 2018 Mar 19; 15(1):88. Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B. PMID: 29554927; PMCID: PMC5859439.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    19. CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. PLoS One. 2017; 12(8):e0182647. Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H. PMID: 28797088; PMCID: PMC5552348.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    20. Primary Progressive Multiple Sclerosis: Putting Together the Puzzle. Front Neurol. 2017; 8:234. Abdelhak A, Weber MS, Tumani H. PMID: 28620346; PMCID: PMC5449443.
      View in: PubMed   Mentions: 17  
    21. Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? Int J Mol Sci. 2015 Jul 31; 16(8):17565-88. Abdelhak A, Junker A, Brettschneider J, Kassubek J, Ludolph AC, Otto M, Tumani H. PMID: 26263977; PMCID: PMC4581209.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells